Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belzutifan - Peloton Therapeutics

X
Drug Profile

Belzutifan - Peloton Therapeutics

Alternative Names: MK 6482; PT-2977; WELIREG; WELIREGTM

Latest Information Update: 13 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Peloton Therapeutics
  • Developer Eisai Inc; Merck & Co; Merck Sharp & Dohme; Peloton Therapeutics
  • Class Antineoplastics; Benzonitrile; Fluorobenzenes; Indenes; Small molecules; Sulfones
  • Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Von Hippel-Lindau disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Von Hippel-Lindau disease
  • Phase II Neuroendocrine tumours; Solid tumours
  • Phase I/II Prostate cancer
  • Discontinued Iron overload

Most Recent Events

  • 31 May 2024 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Renal cell carcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 May 2024 Efficacy and adverse events data from phase I/II LITESPARK-001 trial in Renal cell carcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 24 May 2024 Merck Sharp & Dohme plans a phase II trial for HER2-negative-breast-cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) (PO, Tablet) (NCT06428396)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top